Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Autobio Diagnostics is a company mainly engaged in development, manufacture and sales of diagnostics products.

Part of Beijing Wanger Biotechnology Co. Ltd., Beijing Kwinbon Biotechnology Co., Ltd. is a company headquartered in Changping District, China, that operates as testing laboratory specialized in research and development of rapid detection instrument and immunodiagnostic reagents for food safety.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Applied Biosystems is one of the various brands under the Life Technologies brand of Thermo Fisher Scientific corporation. The brand is focused on integrated systems for genetic analysis, which include computerized machines and the consumables used within them (such as reagents).

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Zhengzhou Danuo Biotechnology Co., Ltd., established on 2017-08-10, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;software development;software sales;Retailing of computer software, hardware and auxiliary equipment(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes the Ribomic Aptamer Therapeutics (RiboART) system to discover new drugs that are applicable to target proteins. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.

Zhongshan Bioengineering Co., Ltd., established on 1991-07-03, Business scope includes pharmaceutical production;Pharmaceutical business;second,Three types of medical device manufacturers;second,Three types of medical device operating enterprises;Production,Sales:Class I medical device;Import and export of goods and technology;Medical technology research and development;lease:First,two,Class III Medical Devices;Own house rental.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Beijing Wanger Biotechnology Co., Ltd. is a technology company specializing in food safety research and development. The company integrates researching, manufacturing, marketing and servicing, and it is the industrialization base of many national scientific programs and projects in China. The company was set up in 2002 and is headquartered in Beijing, CN.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.